Taribavirin

Summary

Taribavirin (CHEMBL2111108) is a phase-3 clinical-stage small molecule; indicated across 1 condition including chronic hepatitis c virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 243.22 Da · C8H13N5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111108
Name	Taribavirin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	451448
Molecular formula	C8H13N5O4
Molecular weight	243.22
InChIKey	NHKZSTHOYNWEEZ-AFCXAGJDSA-N

SMILES: C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=N)N

IUPAC name: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide

Also known as: Taribavirin, Taribavirina, Taribavirine, TARIBAVIRIN

Parent form; salt/anhydrous children: CHEMBL2107375

Patent coverage: 595 distinct patent families (2,449 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic hepatitis C virus infection	2	MONDO:0005354	EFO:0004220

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00446134	PHASE2	COMPLETED	Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).